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Abstract
Copy Number Aberration (CNA) in myelodysplastic syndromes (MDS) study using single nucleotide polymorphism (SNP)
arrays have been received increasingly attentions in the recent years. In the current study, a new Constraint Moving Average
(CMA) algorithm is adopted to determine the regions of CNA regions first. In addition to large regions of CNA, using the
proposed CMA algorithm, small regions of CNA can also be detected. Real-time Polymerase Chain Reaction (qPCR) results
prove that the CMA algorithm presents an insightful discovery of both large and subtle regions. Based on the results of
CMA, two independent applications are studied. The first one is power analysis for sample estimation. An accurate
estimation of sample size needed for the desired purpose of an experiment will be important for effort-efficiency and cost-
effectiveness. The power analysis is performed to determine the minimum sample size required for ensuring at least 100l%
(0vlƒ1) detected regions statistically different from normal references. As expected, power increase with increasing
sample size for a fixed significance level. The second application is the distinguishment of high-grade MDS patients from
low-grade ones. We propose to calculate the General Variant Level (GVL) score to integrate the general information of each
patient at genotype level, and use it as the unified measurement for the classification. Traditional MDS classifications usually
refer to cell morphology and The International Prognostic Scoring System (IPSS), which belongs to the classification at the
phenotype level. The proposed GVL score integrates the information of CNA region, the number of abnormal chromosomes
and the total number of the altered SNPs at the genotype level. Statistical tests indicate that the high and low grade MDS
patients can be well separated by GVL score, which appears to correlate better with clinical outcome than the traditional
classification approaches using morphology and IPSS sore at the phenotype level.
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Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group
of clonal hematopoietic disorders characterized by peripheral
cytopenia, morphologic dysplasia and susceptibility to leukemic
transformation [1,2]. The classification systems include French-
American-British (FAB), World Health Organization (WHO) and
Internation Prognostic Scoring System (IPSS). Cytogenetic
abnormality is one of the most determinants in the prognosis.
While a large database of cytogenetic data based on metaphase
karyotyping is generated in MDS, and only about 50% clonal
abnormalities of primary MDS are detected by conventional
cytogenetic studies [3–5]. Additionally, there is evidence suggest-
ing that MDS may start with multiple minor clones [6], which may
be missed with conventional cytogenetic studies at the initial
presentation. The detection of copy number variants and related
studies of MDS using single nucleotide polymorphism (SNP) array
data has received increasing attention in recent years and is used
as a powerful tool for molecular karyotyping.
This article is concerned with our latest MDS study using 250 K
Affymetrix SNP arrays. In contrast to other research groups, who
used unsorted bone marrow samples [3–9], we employ flow
cytometry sorting to sort 12 MDS marrow samples into four
different fractions: blastic, erythorid, immature myeloid and
lymphoid. We also exact oral mucosa DNA from buccal swab as
the constitutive DNA samples for each patient. The 250 K SNP
microarray analysis is only conducted with fractions, containing
enough DNA. Using cell sorting, 35 arrays can be generated from
the various fractions derived from 12 MDS patients. This set is split
in a test set and normal references consisting 21 and 14 arrays,
respectively (See Table S1 in supplementary material for details).
One goal of SNP array studies is to detect the regions of Copy
Number Aberration (CNA) in the whole genome. Traditional
methods to infer the copy number from a SNP array can be
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Olshen et al.[10] proposed a new algorithm called Circular Binary
Segmentation (CBS), which models the data explicitly as a series of
segments, with unknown boundaries and heights, and then one
can set up some performances or optimize an objective function.
In [11], the authors fitted the data to specific models, such as
hidden Markov models, which is implemented in the software
CNAG (Copy Number Analyser for GeneChipH). And in [12] the
authors considered LASSO type regression. The principle of SNP
arrays is very similar to DNA microarrays. SNP arrays contain
hundreds of thousands of immobilized sequences with individual
SNPs and only parts of them have CNA. However, CNA of
individual SNP or very few consecutive SNPs might be caused by
noise. One key question is how patterns with altered SNPs can be
selected first. Therefore, we propose to use a so-called Constraint
Moving Average (CMA) algorithm. To detect the abnormal
regions, the results of this approach are validated by real-time
Polymerase Chain Reaction (qPCR). This pattern-selection based
method picks up the subsets of copy number altered SNPs from
hundreds of thousands of individual SNPs in each array and is
afterwards compared with others, computational and intuitional (a
more detailed description can be found in Materials and Methods
& Discussion and Conclusion). The comparison of the results
indicates that our pattern-selection based CMA algorithm has the
capability to detect both large and subtle results. In order to see
the performance of the CMA algorithm, we also compare the
number of abnormal chromosomes (i.e. the chromosomes that
contain CNA regions) detected by both CMA and CNAG (see the
evaluation of the results in Discussion and Conclusion part). In a
way, it proves that our CMA algorithm sheds lights on clinical
prognosis at the genotype level.
Two independent applications of our CMA algorithm are
studied. The first one is the power analysis. An important aspect
of experimental design is to determine the number of the samples
required in order for the results to be statistically interpretable. It
usually refers to power analysis. To perform power analysis, we
establish a hypothesis first, and then statistical testing is implement-
ed to decidewhether thenull hypothesisisaccepted or rejected.The
power of a test is the probability of getting a statistically significant
result, given that the null hypothesis is false (the flowchart is given in
Result part). Power is proportional to the sample size, significance
level and the effect size, and is also inversely proportional to the
varianceinthe population.Statisticaland biologicalsignificancecan
be linked through the use of power analysis. And once given the
significance level, the effect size and the desired power, the sample
size can be directly estimated for target power.
To estimate the number of the required samples for the purpose
of genotype array studies, there already exist some standard
methods of power analysis. Like in gene microarray studies, people
usually identify the differentially expressed genes across disease
subtypes by employing some algorithms, such as Principle
Component Analysis (PCA), Significance Analysis of Microarrays
(SAM) [13], which are used to solve the typical curse-of-
dimensionality problem, or just simply using the p-value [14] for
the comparison of each gene across the arrays. Then based on the
assumption of homogeneous sampling from the entire population
of each class, statistical hypothesis test are performed to determine
the minimum sample size by using different test statistics. For
instance, two group t-test based on differences of group means
[15], Wilk’s lambda score [16], or nonparametric Wilcoxon rank
sum test based on differences of rank sums in groups [15]. These
algorithms and statistical measurements have already been
adopted and proved effectively. However, these methods are only
valid in the studies with diseases that have significant homogeneity.
However, the methods mentioned above are due to heteroge-
neity of the disease invalid in MDS studies. In our experiments,
copy number variants in the same regions can hardly be found in
SNP arrays from different patients or even in the different
hematopoietic fractions (erythroid, myeloid or blastic fraction
sorted by flow cytometry) of the same patient. To the best of our
knowledge, there is no existing work that attempts to quantify the
statistical power in for MDS studies. The major obstacle of such
kind of work is that the heterogeneity makes it difficult to design
statistical tests and to give an accurate estimated sample size. This
motivated us to consider other approaches to deal with this issue.
Based on the CNA regions selected by the CMA algorithm,
power analysis can be performed to determine which sample size
can ensure that the detected regions are statistically different from
the normal references (details are shown in the Results part). Since
the heterogeneity of MDS leads to fewer common CNA regions (i.e.
CNA regions that are in the same location for different samples)
among the sample arrays, the required sample sizes may vary in
order to make sure that the detected specific regions will be
significantly different from the reference in the sense of statistical
reliability. Therefore, we formulate the problem to detect at least
100l% (0vlƒ1) CNA regions at a desired power. The minimum
number of array samples required in the experiments can then be
estimated by using statistical tests to ensure the statistically
significance and expected power. The adjustable proportional
parameter l allows us to determine the needed sample sizes for
detecting the desired regions. As expected, power increases with
increasing sample size with a fixed significance level.
The second application of our pattern-selection based CMA
algorithm is to identify the different MDS grades of patients. As we
know, the well separated stages of MDS patients (high and low
grades MDS patients) can guide the prognosis and survival analysis.
The existing methods for discrimination of the grade of MDS
patients can refer to both cell morphology and International
Prognostic Scoring System (IPSS) score,which belong to methods at
the phenotypelevel.As already mentioned, due to the heterogeneity
reflected in the SNP arrays to study this complex group of diseases
and consequently the lack of common CNA regions, the traditional
classification approaches generally used for analysis at genotype
level are no longer available Therefore, we need a new approach to
overcome this obstacle. Based on the CMA algorithm, the Risk
Likelihood Function and General Variant Level (GVL) score are
proposed for each array. The GVL score integrates the information
of CNA, such as the number of abnormal chromosomes, the total
numberof altered SNPs, and returna unifiedmeasurement to make
the different arrays comparable. Afterwards related analyses
according to GVL are considered to discriminate between high
and low grade MDS patients. (It is worth to mention that we pay
attention to individual patient instead of single arrays here. If we
have more than one array for one patient, we need to calculate the
GVLforallarraysofthispatient,andthe averageGVLscorewill be
the final GVL score for this patient.) Two group t-tests indicate that
the GVLs are significantly different for high/low grade (defined by
both cell morphology and IPSS score) MDS patients. It gives us a
hint that we can set a critical value of GVL as a classification
criterion for SNP array analysis. .The classification results achieved
with GVL scores at the genotype level appear to be consistent with
that of the cell morphology and the IPSS scores. Since the
discrimination of the high/low grade MDS is an important issue in
the prognosis and the analysis of the chances of survival for the
patient,ourproposedGVLscoregivesananalyticalcriterionforthe
analysis using SNP arrays.
Our novel contributions are: (i) we develop a new pattern-
selection based method to detect the regions of CNA for a
MDS Study by SNP Array
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SNP arrays. Real time PCR results prove that besides large CNA
region, the CMA algorithm also presents an insightful discovery of
subtle regions; (ii) based on the results of the CMA algorithm, two
independent applications are studied. (a) Sample size estimation of
the experiment based on selected patterns can be easily done by
using statistical. (b) According to the results of the CMA algorithm,
the high and low grade MDS patients can be well separated by
using the proposed GVL score, which gives a unified measurement
to make it comparable among the different arrays. (iii) For
comparative analysis, we demonstrate that the number of the
abnormal chromosomes detected by CMA is significantly different
between patients suffering from high grade and those affected by
low grade MDS. Such difference cannot be observed using CNAG.
The comparison of different algorithms indicates that our method
is less complicated and also computable for SNP arrays with high
resolution.
Materials and Methods
The data-set
Altogether, 35 SNP arrays are generated from 12 MDS
patients, 21 and 14 of are treated as test samples and references,
respectively. Genomic DNA from each fraction was extracted with
Qiagen Allprep RNA/DNA Mini Kit (Qiagen Valencia, CA) and
stored at 280uC. Constitutional/control DNA consisted of buccal
mucosa and lymphoid fractions of the patients and one marrow
sample without evidence of MDS sorted into blastic, erythroid,
and myeloid fractions (see Table S1. in supplementary material).
The quality and quantity of genomic DNA were assessed by
NanoDrop ND-1000 spectrophotometer (NANoDrop Technolo-
gies, Wilmington, DE). Genotyping is performed using 250 K
NspI SNP-microarray chips (Affymetrix, UK) and processed
according to the manufacture’s instruction. 250 ng of genomic
DNA was digested with NspI for 2 hours at 37uC followed by
adaptor ligation, PCR amplification, fragmentation, labeling and
hybridization. Three micro-liter of the PCR and 4.5 ul of the
fragmentation product were electrophoresed to confirm the
processing of the DNA. The Affymetrix 450 fluidics station and
the Affymetrix gene scanner were used to wash, stain and scan the
arrays. Signal intensity and SNP calls are analyzed using CNAG
and Genotyping Console.
Due to the high variability of the mean intensities across
different SNP arrays, normalization is necessary to make different
SNP arrays comparable [17]. In this study, the sums of intensities
of the perfect match probes for alleles A and B are normalized
using invariant set method by [18,19]. After normalization, the
log-2-ratio features are extracted using the ‘best-fit’ method also
used in CNAG [20].
Pattern-selection based CMA for CNA region detection
Consider the pair of tumor and normal samples from the same
patient (but different tissue), the SNP is genotype call conflicting in
these pair samples, if the genotype of one SNP is homozygous in
the normal sample, but heterozygous in the tumor sample, or both
are homozygous but have different alleles. In order to reduce the
risk of false positives or false negatives in the final results, SNPs
with conflicting genotype call between samples and references are
filtered right at the beginning. Table 1 displays the number of
SNPs with conflicting genotype calls considering all arrays. It also
the probabilities of such conflicts occur due to random errors,
which are calculated assuming that the observed conflicting SNPs
completely caused by random errors follow the binomial
distribution B(n, p), with the parameters n denoting the total
number of SNP arrays (in our case, n=35) and p being calculated
as follows
p~
# Genotyping Conflicting SNPs
262264|35
, ð1Þ
where 262264 is the total number of the SNPs in one array. Then
the probability of the observed SNPs in all arrays caused by
random error can then be calculated by
Prob random error with k SNPs ðÞ ~
35
k
  
pk 1{p ðÞ
n{k ð2Þ
The smaller the probability is, the higher is the possibility that the
genotype call is wrong.
By virtue of the small probabilities that indicate the conflicting
SNPs appearing at least in 3 of the arrays, only the remaing
235413 (171057+38094+26262) SNPs will be analyzed in the next
stage.
In the next step, we use Genotyping Console to automatically obtain
the list of SNPs spanning over the regions of known CNA or
segmental polymorphism. These SNPs were reported in the
literatures, indicating the occurrence of CNA in healthy
population (population without MDS). By filtering those SNPs,
170795 SNPs in each array are finally left for the further analysis.
On account of CNA in part of the arrays, we need to detect
those regions first. Among the methods for copying number
estimation, CNAG and dChip receive more concerns, especially
CNAG, because CNAG uses a different normalization method
which can remove the baselines of raw data. Both of them use the
Hidden Markov Model (HMM). However in the HMM, only the
current observation and the previous hidden state are employed to
infer the current hidden state, which makes it easily susceptible to
false detections due to strong noisy data. Here we propose a
straightforward method making use of the fact that the copy
Table 1. Results for genotype conflicting analysis for 35 arrays.
# conflicting arrays 0 1 2 3 4 5
# SNPs 171057 38094 26262 10919 7069 3770
Prob. of random errors 0.362959 0.142516 0.036324 0.006756 0.000977
# conflicting arrays 6 7 8 9 10 .10
# SNPs 2384 1242 734 386 216 181
Prob. of random errors 0.000114 1.12E-05 9.22E-07 6.56E-08 4.07E-09 2.33E-10
E.g. there are 3770 genotyping conflicting SNPs, each of which appears in 5 arrays, and if such conflicts are just due to random error (i.e. can not be regarded as wrong
genotyping calls), the probability is 0.000977.
doi:10.1371/journal.pone.0005054.t001
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single or fewer SNPs may not be correct because noise in the data
and therefore we focus on detecting a pattern of copy number
variations in this study. In order to use the contextual cues, a so-
called Constraint Moving Average (CMA) algorithm with length
five is performed. For all the maintained SNPs in genome, ranging
from chromosome 1 to chromosome 22, every five consecutive
SNPs are taken into account as one region. We check the average
log-2 ratio of each region in samples, by comparing them with
their corresponding references. We select a specific region as an
abnormal one if it satisfies the following condition C.
C (1) The mean of the log-2 ratios for a set of consecutive five
SNPs in a region across the chromosomes satisfies either .0.35
or ,20.35, which correspond to the critical values of a copy
number of three and one, respectively.
(2) The standard deviation (SD) of those five log-2 ratios should
be ,0.15.
The threshold of log-2 ratio here is 60.35, the same as in [17].
Finally, all the selected CNA regions in the samples are
recombined in order to exclude the overlapping cases. Figure 1
illustrates the CMA algorithm for MDS-2 Myeloid.
The CMA algorithm reduces the complexity of the model, and
fewer parameters are employed, which makes it robust and easy to
be performed and computable for high resolution SNP arrays. In
addition, the mean of the log-2 ratio gives an intuitional hint of the
real copy number variations and together with the restriction on
the standard deviation. It avoids false positives caused by strong
noises. Compared with the results of CNAG, the proposed CMA
algorithm presents an insightful discovery of subtle regions, which
could be ‘‘missed’’ by other approaches (like CNAG and CBS). The
results are supported by real time PCR. Table 2 shows the region
located in chromosome 7q34 in MDS-3, starting from the 85974
th
SNP and ending at 85978
th SNP. Blast and Erythroid fractions are
used as test samples, and Lymphoid is the corresponding
reference. These three fractions are from the same patient. The
region covers the gene FOXP2. CMA results indicate that,
compared with the reference Lymphoid, only Erythroid has
deletion in this region. The result is supported by real-time PCR
(see Table 2; see also in [21]). However, this CNA region is missed
by CNAG and CBS.
Results
Our CMA algorithm has the capability to detect both large and
subtle regions. The comparison of the results with other algorithms
and the choice of parameters will be discussed in the Discussion
and Conclusion section. The CMA approach has two independent
applications. The first one is the power analysis to estimate the
required sample size that ensures statistical difference between the
detected regions and the normal references. We also want to pay
attention to the MDS patients. Based on the results of the CMA
algorithm, we propose to distinguish the high grade MDS patient
from the low grade one by using the GVL scores. These two
applications are exhibited in the following two subsections.
Minimum sample size estimation by power analysis
Using the pattern-selection based CMA algorithm, the CNA
regions can be detected for each array. Figure 2 is a sketch map of
the CNA regions detected by CMA algorithm. For each selected
CNA regions all across the genome, the behavior may not be
accordant in different arrays. Some appear repeatedly for different
sample arrays (CNA regions marked with green circle), whereas
some others emerge rarely (CNA regions marked with red circle).
The goal of power analysis is to determine the minimum sample
sizes required to ensure that the detected CNA regions are
statistically different from normal references, (rather than
occurring randomly). For a specifically selected CNA region, we
use the average log-2 intensity to estimate the copy numbers. Then
we compare the average intensity of the same regions between
samples and references. The hypothesis of the power analysis can
be formulated as the testing of the null hypothesis H0 against the
alternative hypothesis H1.
Figure 1. Illustration of the CMA algorithm. MDS-2 Lymphoid is the reference, and MDS-2 Erythroid is the test sample. In the test sample, the
average log-2 intensities of every five consecutive SNPs in the circled region are higher than 0.35, with the small SDs (,=0.15). Selected overlapping
regions are merged into a large region.
doi:10.1371/journal.pone.0005054.g001
Table 2. Output of the CMA algorithm results for a region
located in chromosome 7q34 and the corresponding real-time
PCR results.
Sample Fraction Mean SD PCR
MDS-3 Lymphoid (control) 0.0951 0.1220 1
Blast (test sample) 0.1869 0.1724 0.91
Erythroid (test sample) 0.3563 0.1229 0.65
Three fractions from the same patient are displayed. The Lymphoid is the
normal reference. Blast and Erythroid serve as test samples. The log 2 ratio
behaviors them are different. As normal one, the log 2 ratio of Lymphoid is
closed to 0. There is a significant loss in Erythroid, but for Blast, the log 2 ratio is
not low enough. The real time PCR of Lymphoid is normalized as 1. Comparing
with the reference, Erythroid is concluded as copy number aberration. However,
such abnormality can not be observed in Blast.
doi:10.1371/journal.pone.0005054.t002
MDS Study by SNP Array
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samples and references is same (log-2 ratio=0),
H1: For the specific region, the average intensity between
samples and references is significantly different (log-2 ratio?0).
To estimate the sample size, usually one refers to power
analysis. There are four quantities in the power analysis, sample
size, effect size, significance level a and power. With three known,
the fourth will be determined. In statistics, the terms Type I error
(also referred as significance level a, of false positive) and Type II
error (also known as b error, of false negative) are used to describe
possible errors made in a statistical process (the target power is
usually defined as 1{b). They are usually called as ‘‘two sources of
error’’, namely,
a: The error of rejecting a hypothesis that should have been
accepted;
b: The error of accepting a hypothesis that should have been
rejected.
Another principal challenge posed in the field of power analysis
is how to define the effect size. The effect size is a measure of
biological significance. It gives the difference between the results
predicted by the null hypothesis and the actual state of the
population being tested. In a clinical study, when the interest is to
target the power for different effect sizes, sample size can be
estimated to ensure that the endpoint with the smallest effect size is
sufficiently powered with a fixed significance level a. Thus, if the
measurements are meaningful on a practical level, it is encouraged
to give the effect size by one’s experience. One of most accepted
opinions to determine the effect size is the one mentioned in [22],
where 0.2 indicates of a small effect, 0.5 a medium and 0.8 a large
effect size.
Due to the limited amounts of SNP arrays used in our MDS
study, it is difficult to define an appropriate effect size empirically.
Therefore, we prefer to use the standardized effect size from [23],
defined as
di~
mi{m0 jj
SDi
, ð3Þ
for the selected abnormal region i, where m0 is the critical value set
as 0 (the log-2 ratio is 0 if the average intensity is not different
between the samples and the references) in our case, mi and SDi
are the mean and standard deviation of all sample for a specific
region, respectively.
When H0 is true, the test statistic T (see the definition in
Figure 3.) follows t distribution with degree of freedom N{1 (N is
Figure 2. CNA regions selected by CMA algorithm. Compared with the references, the regions with circles indicate the CNA regions. For
different samples, the CNA regions may occur in the different locations. Some appear repeatedly (the ones with green circles), and some others rarely
occur (the ones with red one).
doi:10.1371/journal.pone.0005054.g002
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non-central t distribution with degree of freedom N{1 and non-
central parameter di. Given a type I error a and a type II error b,
and the formulation of effect size di, the power analysis algorithm
for the estimation of minimum sample size follows the flowchart
showing in Figure 3, where Si
  is the estimation standard
deviation of test samples.
Since the repeatability number of each detected CNA region is
different, the effect size varies. It results in altered sample sizes for
the detection of the different specific regions. For some regions, the
effect sizes are so small that we can hardly see any CNA region in
the test samples. Sometimes, only a fraction of the CNA regions
are receiving attentions according to the purposes of experiments.
Especially for those frequently appearing regions, only a fewer
samples will be required for statistical interpretation. While for
rarely emerging regions, we need a huge sample size to ensure the
statistical significance of tests. Therefore, the sample size depends
on the desirability of the study. It does not necessarily require
identification of all abnormal regions at the same time. Accurate
sample size estimation will be important to an efficient and
economical study design. To implement it, we first collect the
abnormal regions derived by CMA algorithm. For each detected
region i, we calculate the corresponding effect size di, and sort
them decreasingly. A proportion parameter l (0vlƒ1) now is
employed, and the number of sample arrays required to detect at
least 100l% can be obtained following the methods shown in the
flowchart of Figure 3, with the effect size chosen as the k-th one in
the decreasing sequence, where k denotes the smallest integer
larger than 100l. Usually, for frequently appearing regions, the
effect sizes are much larger than that of others, which implies that
smaller sample sizes are needed.
According to our CMA algorithm, in total 1117 of the detected
regions are non-overlapping. Power analysis is executed according
to the flowchart in Figure 3. We calculate the effect sizes (See
equation (3)) for each region. The sorted effect sizes range from
0.0004 to 1.062, the median and mean are 0.282 and0.317,
respectively. 889 out of 1117 are less than 0.5, which implies that
most of them are small ones. The average of those less than 0.5
(the 889 ones), is only 0.229 (low), while the average of the rest is
0.652 (high). Figure 4 shows the sample size under different views
of effect size with fixed significance level at 0.05.
Table 3 summarizes the sample sizes needed for a detection
proportion from 40% to 80%. With the estimated sample sizes,
target power can be reached under the most frequently used
significance level 0.1, 0.05, 0.01. As expected, an increase of the
desired proportion increases requires more and more samples.
Since for most of the detected regions, the corresponding effect
sizes calculated by equation (3) are small ones, we suggest that one
can choose effect sizes from 0.2 to 0.3 can be chosen for a rough
estimation.
Figure 3. Power analysis algorithm for the estimation of the
minimum sample size.
doi:10.1371/journal.pone.0005054.g003
Figure 4. Power curves and sample size estimation under different views of effect sizes. The significance level is set as 0.05.
doi:10.1371/journal.pone.0005054.g004
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The discrimination of high and low grade of MDS patient is an
important issue in the prognosis and survival analysis of MDS
studies. Biologists use cell morphology and the IPSS score to
determine the assessment of patient’s MDS severity. Those kinds
of classification are important to clinical survival analysis in the
future. However, at the genotype level, to the best of our
knowledge, there is no relative research focusing on this issue. As
an application of the proposed CMA algorithm, we first define the
Risk Likelihood Function and the General Level (GVL) score as in
(4) and (5); then the GVL score will be used for the discrimination
between the high and low grade MDS. Some statistical tests show
that, high and low grade MDS can be well separated by the
definition of GVL. The difference between the two groups is
significant, which implies that it can give a quantitative criterion
for the classification when using SNP arrays.
The Risk Likelihood Function. The Risk Likelihood
Function defined as follows, takes account of two aspects, one is
the chromosome abnormalities, and other one is the number of
altered SNPs.
fn i,li ðÞ ~
1
3
ln 1z
ni
n
  
z
2
3
1{e{li=5   
, ð4Þ
where ni is the number of abnormal chromosomes in array i, n
stands for the average abnormal chromosome of the test samples,
and li denotes the total number of the abnormal SNPs across the
genome in array i, setting the denominator as 5 in the power due
to the length of the CMA algorithm (also see Materials and
Methods). The first term focuses on the proportion of abnormal
chromosomes across the whole array. Since the slowly varying
function ln 1zx ðÞ *x,a sx?0, when there are a fewer the
abnormal chromosomes (ni is small), it will not change much; but
for the larger one, it varies slowly. The slowly varying function will
eliminate the influence of extremely large or small ni. The second
part is an analogy to the Haldane map function defined in hidden
Markov model [18]. Besides the altered SNPs, the risk function
also includes the number of abnormal chromosomes of individual
SNP array, and the overall average number of abnormal
chromosomes of the all population. Obviously, the array with
more abnormal chromosomes and more altered SNPs will suffer
high risk.
The General Variant Level (GVL). The General Variant
Level presenting the log-2 ratio variant with the Risk Likelihood
Function can be defined as
gi~fn i,li ðÞ
X ni
j~1
vi,j si,j
       , ð5Þ
where si,j
        describes the absolute value of average intensities of the
j-th chromosome in array i. The GVL integrates the risk function
and quantity of CNA regions with weights vi,j. It depicts the
overall information of the SNP array. Here we take the absolute
values of the average intensities, because our hypothesis focuses on
whether the copy number changes or not for the samples changes
in contrast to the references. We only need to see how far they
deviate from normal. We give the weights vi,j to the absolute value
of average intensities according to the proportion of the number of
the abnormal regions appearing in all samples. For instance, in the
Myeloid fraction of MDS-7, there are three abnormal
chromosomes, chromosome 3, 4 and 18. In the total of 21
samples, 4 arrays contain abnormal regions in chromosome 3, 6
arrays in chromosome 4, and 5 arrays in chromosome 18. Hence,
in this case the weight v is v~ v7,1,v7,2,v7,3 ðÞ ~ 4
15, 6
15, 5
15
  
.
Though there are only a few common regions among the
sample arrays, using the proposed CMA algorithm and the GVL
score, we make the arrays comparable. Thereby, high and low
grade MDS patients can be well separated. Table 4 displays the
discrimination of 12 severe and less affected patients by
morphology and IPSS score. The 12 patients are separated into
two groups by morphology; one is high grade (H), and other is low
grade (L). By IPSS, there are four different grades, i.e. low (L),
inter-median I (Int-1), inter-median II (Int-2), and high (H). We
merge the low and inter-median I as a low group; inter-median II
and high as a high group in IPSS classification. Then for each
array, we calculate its GVL.
From Table 4, we notice that the number of abnormal
chromosomes for the low grade MDS cases is usually less than
5, in contrast to the high grade ones. Also, the total number of the
altered SNPs is much smaller for low grade MDS (,=30) than
that of high grade one. The argument of the classification results
by cell morphology is acceptable in the sense that to set critical
value of the average GVL score of a patient as 0.2. MDS-7 is a
special case. The morphological classification shows no significant
evidence to which grade it belongs. It is claimed as uncertain.
However, by our CMA algorithm and the GVL score calculation,
its two fractions exhibit different behaviors, with lower GVL score
in the Myeloid and higher GVL score in Blast. However, the
Table 3. Sample size estimation to detect at least l~0:4, 0.5, 0.6, 0.7 and 0.8 truly altered regions for the desired power up to 0.8
and 0.9, with different significance level.
l d a~0:1 a~0:05 a~0:01
P=0.8 P=0.9 P=0.8 P=0.9 P=0.8 P=0.9
0.4 0.344 54 74 69 91 102 129
0.5 0.283 79 109 101 134 150 190
0.6 0.230 118 163 150 200 224 284
0.7 0.171 215 296 272 364 406 516
0.8 0.108 528 731 671 897 998 1271
(P: Power).
doi:10.1371/journal.pone.0005054.t003
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1. Although it classified to high grade by cell morphology,
according to IPSS score, it is a low grade MDS. However, we can
see a large scale of deletion in chromosome 7 for both Blast and
Erythroid fractions; hence the average GVL for this patient is
high. Since the GVL of MDS-1 is in favor of the classification
result by morphology, we have reason to define MDS-1 as high
grade.
Based on the classification results by cell morphology and IPSS
score, we perform the two-group t-tests to compare the GVL
between high and low grade MDS. Results are listed in Table 5.
The tests include two cases; one is without the uncertain MDS-7,
and the other is with MDS-7. The p-value shows that the GVL
scores of two groups are significantly different, which indicates that
high and low grade MDS can be well separated by using the
proposed GVL score. Even though the GVL results tend to have a
minor discrepancy compared with IPSS, the t-test results can still
prove the significance difference between two groups. Therefore,
the results of GVL appear to correlate better with clinical outcome
than the traditional classification approaches using cell morphol-
ogy and IPSS score.
Discussion
With the proposed CMA algorithm, we detect the CNA regions
using the mean and SD of every five consecutive SNPs as criteria.
Actually, computing the mean in a region can be regarded as a
constant regression to predict the real log-2 ratios. We have also
tried different methods than constant regression, such as local
linear regression, quadratic regression to select the CNA regions
by the threshold of mean and SD. Most of the selected CNA
regions of CMA algorithm can be included by performing the
local linear regression, because the local linear regression will not
change the mean of a region. However, due to the correction of
SD, it almost abolishes the restriction of SD, which leads to
overestimation, especially in the case of heavy noise data. Since the
quadratic regression will essentially change both the mean and SD
of a specific regions and cannot give an intuitionist view of the log-
2 ratio, hence it is not robust enough.
Statistical approaches for analyzing copy number data are
aimed at detecting the regions of genomic alteration. One
Table 4. The average GVL of MDS patients and the discrimination between the high grade MDS and the low grade MDS by both
cell morphology and IPSS score.
Sample Fraction ni li GVL Average
High/Low by
morphology IPSS
MDS-1 Blast 8 365 0.3871 0.3835 H Int-1
Erythroid 6 53 0.3799
MDS-2 Myeloid 12 74 0.3581 0.4011 H Int-2
Erythroid 15 174 0.4441
MDS-6 Blast 4 16 0.3336 0.2725 H Int-2
Erythroid 3 15 0.3119
Myeloid 1 6 0.1719
MDS-8 Blast 5 1610 0.3635 0.3561 H Int-1
Erythroid 3 875 0.3286
MDS-10 Myeloid 6 4586 0.3742 0.3742 H H
MDS-3 Blast 0 0 0 0.1123 L Int-1
Myeloid 0 0 0
Erythroid 4 30 0.3369
MDS-4 Myeloid 0 0 0 0.0895 L L
Erythroid 1 5 0.1790
MDS-5 Erythroid 1 5 0.1808 0.1808 L L
MDS-9 Erythroid 1 5 0.1939 0.1939 L L
MDS-11 Myeloid 0 0 0 0 L Int-1
MDS-12 Myeloid 0 0 0 0 L Int-1
MDS-7 Blast 15 198 0.4264 0.3842 uncertain Int-1
Myeloid 3 38 0.3421
A GVL of zero implies that there is no selected abnormal region in the corresponding arrays.
doi:10.1371/journal.pone.0005054.t004
Table 5. Two group t-test results for the discrimination of
MDS grade of using General Variant Level score in the sense
of cell morphology and IPSS.).
Morphology IPSS
Without MDS-7 t-value df p-value t-value df p-value
9.3989 9 0.0001 4.2432 9 0.0022
With MDS-7 t-value df p-value t-value df p-value
5.6028 10 0.0002 3.6182 10 0.0047
The cutoff value of copy number one and three in CNAG is 20.35 and 0.35, and
the window size of moving average is 5. The t-value is the value of statistics in
the t test, and df is the degree of freedom of the test.
doi:10.1371/journal.pone.0005054.t005
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segments, with unknown boundaries and heights, and then one
can set up some performances or optimize an objective function,
like proposed in [19] to use a new algorithm called Circular Binary
Segmentation (CBS). Others have fitted the data as specific
models, such as hidden Markov model in [18], and LASSO type
regression in [20]. In essence, our algorithm is a kind of regression-
based method. We compare it with other methods to evaluate its
efficiency and the accuracy the results. First of all, we use the
LASSO based penalized least square estimation discussed in [20].
We define the same cutoff values as the authors. However, the
algorithm fails when applied to our data. It takes more than
6 hours for each sample array to run, but nothing can be found.
The examples shown in [20] are CGH data with about
2000 points in each array, whereas our data set contains 250 K
single SNPs in each array. The failure might occur because the
LASSO based method is time-consuming for high resolution SNP
array. Table 4 compares the selected abnormal regions in
chromosome 7 by CMA (regression based method) algorithm
with CNAG (HMM based method) and CBS (segmentation based
method). When the abnormal regions are large, the results are
consistent for the different methods. However, although HMM
used in CNAG gives a reasonable inference of copy numbers, it
does not treat the log-2 ratio in a local region as a pattern, some
individual SNPs are reported as abnormal ones, which are not
reliable. Sometimes CBS can find many small regions with very
fewer altered SNPs, but the SDs of these regions may be much
larger than what we expected, which results in a high number of
false positives. Furthermore we want to take a look at the mean
and the SD of the remaining regions that were found by CNAG
and CBS, but missed with the CMA algorithm in Table 6. As
displayed in the brackets, the CMA algorithm drops those regions
mainly because that some of them consist just single altered SNPs,
which might be caused by the noise in the data; and also because
some dissatisfy the thresholds (the fluctuations (SD) in a local
region are too large). This implies that the proposed CMA
algorithm is robust. Another advantage is that the CMA algorithm
dramatically reduces the complexity of the model, and enables an
insightful discovery for subtle discovery.
Next we want to compare the CNA regions discovered with the
CMA algorithm and CNAG. The average number of chromosomes
containing CNA regions and the corresponding standard devia-
tions are listed in Table 7. The parameters in CNAG are set
consistent with CMA, i.e. the length of moving average is 5 (the
default is 10); the cutoff values of copy number one and three are
20.35 and 0.35, respectively (the default are 20.49 and 0.30,
respectively). Using the CMA algorithm, the classification results
for cell morphology show that the number of abnormal
chromosomes that CNAs (for cases with multiple fractions tested,
the average abnormal chromosomes of all fractions are used) is
significantly smaller (p-values are close to zero) in low grade MDS
cases than it is in patients with high MDS cases using CMA. Such
difference cannot be observed by CNAG. The same conclusions
can be made in IPSS scores classification. In addition, more
comparisons with different parameters in CNAG are made. Notice
that a chromosome may only have one single altered SNP
according to the CNAG’s output; therefore, we also exclude those
chromosomes in the comparison in order to reduce the false
positives. The conclusion is quite similar as what we display is
Table 7 (See Table S2, S3, S4 in supplementary material for
details).
At last we want to discuss the length of CMA algorithm, as it is a
critical parameter for the success of our study. Notice that the
overlapping regions selected by the CMA algorithm will be
merged to large and non-overlapping regions; therefore, the length
of final copy number aberration regions may not be fixed at five.
In this study, we can regard the length five as an initial length. Our
choice is based on the real-time PCR results, indicating that the
copy number aberration region will not be selected, if we change
the length to six, due to the dissatisfaction of both mean and SD
Table 6. Comparison of selected abnormal regions in
chromosome 7 by CMA algorithm, CNAG and CBS. Y and N
denote if the region is selected or not, respectively.
Arrays Regions CMA CNAG CBS
MDS-8 B Chr 7 monosomy (validated by PCR) YY Y
MDS-8 E Chr 7 monosomy (validated by PCR) YY Y
MDS-1 B 7q34–7q36.1 Y Y Y
MDS-3 E 7q34 (validated by PCR) YN N
MDS-1 B 7p21.3 Y N N
MDS-2 E 7p14.2 Y N N
MDS-1 E 7q14.1 (mean=0.56; SD=0.47) N Y N
MDS-1 E 7q34 (mean=0.25; SD=0.20) N Y N
MDS-2 E 7p31.1 (mean=0.24; SD=0.34) N Y N
MDS-2 M 7p31.3 (single SNP) N Y N
MDS-2 M 7q34 (mean=0.29; SD=0.28) N Y N
B: Blast; E: Erythroid.
doi:10.1371/journal.pone.0005054.t006
Table 7. Copy number aberrations comparison of CMA algorithm and CNAG (MDS-7 is excluded).
CMA HLt-value df p-value
mean SD mean SD
Morphology 5.93 2.83 0.64 0.56 7.07 9 0.0001
IPSS 6.22 3.67 1.85 2.44 4.72 0.0011
CNAG HLt-value df p-value
mean SD mean SD
Morphology 14.30 2.96 9.17 5.03 2.01 9 0.0753
IPSS 12.38 1.67 11.18 5.68 0.35 0.7344
Two-group t-test are performed under the null hypothesis, that mean of two groups are no significant different.
doi:10.1371/journal.pone.0005054.t007
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for a length of five are 20.356269 and 0.1229, respectively.
However, they change to 20.296754 and 0.1826 for a length of
six. Furthermore, we think that if the initial length is too short, we
may find much more false positive regions. By trying different
lengths, we conclude that the proposed one of five is the most
suitable and it can be the minimum length for the selection of
CNA regions. However, the user may change the initial length
appropriate to the data. If the user has prior knowledge about the
data, we recommend that the initial length should be chosen
according to the prior information.
Supporting Information
Table S1 Details of the used SNP arrays. The references are
marked in shade.
Found at: doi:10.1371/journal.pone.0005054.s001 (0.05 MB
DOC)
Table S2 Copy number aberrations comparison of CMA
algorithm and CNAG (MDS-7 is excluded). The cutoff value of
copy number one and three in CNAG is 20.35 and 0.35, and the
window size of moving average is 5 (chromosomes with only single
altered SNP excluded). Two-group t-test are performed under the
null hypothesis that the means of two groups are no significant
different.
Found at: doi:10.1371/journal.pone.0005054.s002 (0.03 MB
DOC)
Table S3 Copy number aberrations comparison of CMA
algorithm and CNAG (MDS-7 is excluded). The cutoff value of
copy number one and three in CNAG is 20.49 and 0.30 (default
setting), and the window size of moving average is 5. Two-group t-
test are performed under the null hypothesis that the means of two
groups are no significant different.
Found at: doi:10.1371/journal.pone.0005054.s003 (0.03 MB
DOC)
Table S4 Copy number aberrations comparison of CMA
algorithm and CNAG (MDS-7 is excluded). The cutoff value of
copy number one and three in CNAG is 20.49 and 0.30 (default
setting), and the window size of moving average is 5 (chromosomes
with only single altered SNP excluded). Two-group t-test are
performed under the null hypothesis that the means of two groups
are no significant different.
Found at: doi:10.1371/journal.pone.0005054.s004 (0.03 MB
DOC)
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